Dendreon Shares Still Rising (DNDN)
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Shares of Dendreon Corp. (NASDAQ: DNDN) rose nearly 50% yesterday following an announcement that sales of the company’s prostate cancer drug, Provenge, were rising. The pricey drug, which costs $93,000 for a month-long course of treatment, contributed about $82 million to Dendreon’s revenues in the fourth-quarter.
Dendreon shares are up another 6% this morning, at $11.27 in a 52-week range of $6.46-$43.96. Most of the drop from the 52-week high was based on worries about the high cost of Provenge.
Contact [email protected] for any questions or corrections.